Richard Alan Engh


Professor, Biomolecular and Structural Chemistry, Norstruct

Job description

Professor, Biomolecular and Structural Chemistry, Norstruct


  • Philip Ben Rainsford, Fredrik G. Rylandsholm, Martin Jakubec, Mitchell Silk, Eric Juskewitz, Johanna Ulrica Ericson et al.:
    Label-free measurement of antimicrobial peptide interactions with lipid vesicles and nanodiscs using microscale thermophoresis
    Scientific Reports 2023 ARKIV / DOI
  • Robin Lorenz, Jian Wu, Friedrich W. Herberg, Susan Taylor, Richard Alan Engh :
    Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics
    Biochemistry 2021 DOI
  • Wenche Stensen, Ulli Rothweiler, Richard Alan Engh, Melissa R. Stasko, Ilya Bederman, Alberto C. S. Costa et al.:
    Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome
    Pharmaceuticals 2021 ARKIV / FULLTEKST / DOI
  • Krzysztof Tarnowski, Maria Klimecka, Arkadiusz Ciesielski, Grazyna Goch, Anna Kulik, Halina Fedak et al.:
    Two SnRK2-Interacting Calcium Sensor Isoforms Negatively Regulate SnRK2 Activity by Different Mechanisms
    Plant Physiology 2020 ARKIV / DOI
  • Kazi Asraful Alam, Osman Gani, Richard Alan Engh :
    Inhibitor binding of mutants of protein kinase A with GGGXXG and GXGXXA glycine-rich loop motifs
    Journal of Molecular Recognition 2020 DOI
  • Anna Lucja Czarna, Wang Jinhua, Diana Zelencova, Yao Liu, Xianming Deng, Hwan Geun Choi et al.:
    Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors
    Journal of Medicinal Chemistry 2018 ARKIV / DOI
  • Balmukund Thakkar, John Sigurd Mjøen Svendsen, Richard Alan Engh :
    Density Functional Studies on Secondary Amides: Role of Steric Factors in Cis/Trans Isomerization
    Molecules 25. September 2018 SAMMENDRAG / DATA / FULLTEKST / ARKIV / DOI
  • Balmukund Thakkar, Richard Alan Engh :
    Comparative conformational analyses and molecular dynamics studies of glycylglycine methyl ester and glycylglycine N -methylamide
    RSC Advances 24. January 2018 ARKIV / FULLTEKST / DOI
  • Balmukund Thakkar, Marte Albrigtsen, John Sigurd Mjøen Svendsen, Jeanette hammer Andersen, Richard Alan Engh :
    Biofocussed chemoprospecting: An efficient approach for drug discovery
    Chemical Biology and Drug Design (CB&DD) 13. June 2017 FULLTEKST / SAMMENDRAG / DOI
  • Dilip Narayanan, Osman Gani, Franz Gruber, Richard Alan Engh :
    Data driven polypharmacological drug design for lung cancer: Analyses for targeting ALK, MET, and EGFR
    Journal of Cheminformatics 2017 ARKIV / DOI
  • Clemens Joachim Woywod, Franz Gruber, Richard Alan Engh, Tor Flå :
    Dynamical models of mutated chronic myelogenous leukemia cells for a postimatinib treatment scenario: Response to dasatinib or nilotinib therapy
    PLOS ONE 2017 ARKIV / DOI
  • Balmukund Thakkar, John Sigurd Mjøen Svendsen, Richard Alan Engh :
    Cis/Trans Isomerization in Secondary Amides: Reaction Paths, Nitrogen Inversion and Relevance to Peptidic Systems
    Journal of Physical Chemistry A 15. August 2017 FULLTEKST / DOI
  • Ulli Rothweiler, Wenche Stensen, Bjørn Olav Brandsdal, Johan Isaksson, Frederick Alan Leeson, Richard Alan Engh et al.:
    Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules
    Journal of Medicinal Chemistry 2016 DOI
  • Taavi Ivan, Erki Enkvist, Birgit Viira, Ganesh babu Manoharan, Gerda Raidaru, Alexander Pflug et al.:
    Bifunctional ligands for inhibition of tight-binding protein-protein interactions
    Bioconjugate chemistry 2016 DOI
  • Ulli Rothweiler, Jonas Eriksson, Wenche Stensen, Frederick Alan Leeson, Richard Alan Engh, John Sigurd Svendsen :
    Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors
    European Journal of Medicinal Chemistry 2015 DOI
  • Marina Alexeeva, espen Åberg, Richard Alan Engh, Ulli Rothweiler :
    The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
    Acta Crystallographica Section D: Biological Crystallography 2015 ARKIV / DOI
  • Birgit S. Lauber, Leo A. Hardegger, Kazi Asraful Alam, Bjarte Aarmo Lund, Oliver Dumele, Michael Harder et al.:
    Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction Network: Inhibition of PKA and a PKB Mimic
    Chemistry - A European Journal 18. November 2015 DOI
  • Eric Martin, Stefan Knapp, Richard Alan Engh, Henrik Moebitz, Thibault Varin, Benoit Roux et al.:
    Perspective on computational and structural aspects of kinase discovery from IPK2014
    Biochimica et Biophysica Acta - Proteins and Proteomics 2015 DOI
  • Osman A.B.S.M. Gani, Balmukund Thakkar, Dilip Narayanan, Kazi Asraful Alam, Peter Kyomuhendo, Ulli Rothweiler et al.:
    Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches
    Biochimica et Biophysica Acta - Proteins and Proteomics 2015 FULLTEKST / DOI
  • Anna L Illert, Anna K. Seitz, Christoph Rummelt, Stefanie Kreutmair, Richard Alan Engh, Samantha Goodstal et al.:
    Inhibition of aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and aurora kinases R763/ AS703569 and PHA-739358 in BCR-ABL transformed cells
    PLOS ONE 2014 ARKIV / DOI
  • Osman A.B.S.M. Gani, Dilip Narayanan, Richard Alan Engh :
    Evaluating the Predictivity of Virtual Screening for Abl Kinase Inhibitors to Hinder Drug Resistance
    Chemical Biology and Drug Design (CB&DD) 2013 ARKIV / DOI
  • Alexander Pflug, Kenneth Johnson, Richard Alan Engh :
    Anomalous dispersion analysis of inhibitor flexibility: a case study of the kinase inhibitor H-89
    Acta Crystallographica. Section F : Structural Biology and Crystallization Communications 2012 ARKIV / DOI
  • espen Åberg, Bjarte Aarmo Lund, Alexander Pflug, Osman A.B.S.M. Gani, Ulli Rothweiler, Taiana Maia De Oliveira et al.:
    Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool
    Biological chemistry 2012 DOI
  • Kine Østnes Hanssen, Jeanette hammer Andersen, Trine Stiberg, Richard Alan Engh, Johan Svenson, Anne-Marie Genevière et al.:
    Antitumoral and Mechanistic Studies of Ianthelline Isolated from the Arctic Sponge Stryphnus fortis
    Anticancer Research 2012
  • Taiana Maia De Oliveira, Rafi Ahmad, Richard Alan Engh :
    VX680 Binding in Aurora A: pi-pi Interactions Involving the Conserved Aromatic Amino Acid of the Flexible Glycine-Rich Loop
    Journal of Physical Chemistry A 2011 DOI
  • Ulli Rothweiler, espen Åberg, Kenneth Johnson, Tom Egil Hansen, Jorunn B Jørgensen, Richard Alan Engh :
    p38 alpha MAP Kinase Dimers with Swapped Activation Segments and a Novel Catalytic Loop Conformation
    Journal of Molecular Biology (JMB) 2011 DOI
  • N. von Bubnoff, S.P. Gorantla, Richard Alan Engh, Taiana Maia De Oliveira, S. Thöne, espen Åberg et al.:
    The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro
    Oncogene 2011 DOI
  • Rama Krishna Kancha, Nikolas von Bubnoff, Natalie Bartosch, Christian Peschel, Richard Alan Engh, Justus Duyster :
    Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
    PLOS ONE 2011 DOI
  • ME Prime, SM Courtney, FA Brookfield, RW Marston, V Walker, J Warne et al.:
    Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase
    Journal of Medicinal Chemistry 2011 DOI
  • Alexander Pflug, Taiana Maia De Oliveira, Dirk Bossemeyer, Richard Alan Engh :
    Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase
    Biochemical Journal 2011 DOI
  • Osman A.B.S.M. Gani, Richard Alan Engh :
    Protein kinase inhibition of clinically important staurosporine analogues
    Natural product reports (Print) 2010 DOI
  • Alexander Pflug, Jevgenia Rogozina, Darja Lavogina, Erki Enkvist, Asko Uri, Richard Alan Engh et al.:
    Diversity of Bisubstrate Binding Modes of Adenosine Analogue-Oligoarginine Conjugates in Protein Kinase A and Implications for Protein Substrate Interactions
    Journal of Molecular Biology (JMB) 2010 DOI
  • N von Bubnoff, Richard Alan Engh, espen Åberg, J Sanger, C Peschel, J Duyster :
    FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
    Cancer Research 2009 DOI
  • Richard Alan Engh :
    Diversity of target profiles for ABL kinase inhibitors
    2019
  • Richard Alan Engh :
    Protein structures "in crystallo" and "in vivo: do they match? Are they useful?
    2018
  • Richard Alan Engh :
    Prospects for linking TKI protein kinase inhibition profiles to CML modelling parameters
    2017
  • Balmukund Thakkar, Osman Gani, Richard Alan Engh :
    Practical Applications of Informatics Tools to Identify Drug Targets for Novel Compounds from Bio- and Chemoprospecting
    2016
  • Kazi Asraful Alam, Ulli Rothweiler, Richard Alan Engh :
    Static and dynamic interactions between the glycine-rich loop of protein kinases and ATP site inhibitors
    2016
  • Marina Alexeeva, espen Åberg, Richard Alan Engh, Ulli Rothweiler :
    The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
    2016
  • Marc Boomgaren, Osman Gani, Richard Alan Engh, Jørn H Hansen :
    Bioactive Heterocycle Libraries for Anticancer Drug Discovery - Development of Covalent Binding TK Inhibitors
    2016
  • Richard Alan Engh :
    Unpredictable protein kinase flexibility: curse or blessing for inhibitor discovery?
    2016
  • Balmukund Thakkar, Richard Alan Engh :
    PKA to Rho Kinase (ROCK): Assessing Structural Similarity via Surrogates
    2015
  • Marc Boomgaren, Osman A.B.S.M. Gani, Richard Alan Engh, Jørn H Hansen :
    Bioactive Heterocycle Libraries for Anticancer Drug Discovery
    2015
  • Kazi Asraful Alam, Richard Alan Engh :
    Selectivity Determinants of Aurora Kinases
    2015
  • Kazi Asraful Alam, Richard Alan Engh :
    The Glycine Rich Loop As Selectivity Determinant For Protein Kinase Inhibitors
    2015
  • Balmukund Thakkar, John Sigurd Mjøen Svendsen, Richard Alan Engh :
    Design and Synthesis of diverse Piperazine-2,5-diones and their uncyclized analogues as potential kinase inhibitors
    2013
  • espen Åberg, Ole Morten Seternes, Richard Alan Engh, Franz Gruber :
    Fra Mutasjon til Medisin
    2013
  • Balmukund Thakkar, Jørn H Hansen, Richard Alan Engh :
    Design and Synthesis of Tartaric Acid Bisamides: Focus on Kinase Inhibition
    2013
  • Franz Gruber, Thomas Ernst, Kimmo Porkka, Richard Alan Engh, ingvild Mikkola, Jacqueline Maier et al.:
    Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    Leukemia 2012 DOI
  • RK Kancha, N. von Bubnoff, N Bartosch, C. Peschel, Richard Alan Engh, J. Duyster :
    Irreversible inhibitors overcome lapatinib resistance due to ERBB2 kinase domain mutations
    Onkologie (Basel) 2011

  • The 50 latest publications is shown on this page. See all publications in Cristin here →

    Publications outside Cristin

    from PubMed

    from Google Scholar

     

     


    Research interests

    Enzyme-ligand interactions, especially protein kinases

    Drug design

    Cheminformatics